Trial reportJAMA2011
KIT as a therapeutic target in metastatic melanoma.
Trial report in JAMA, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 360 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of Imatinib Mesylate (STI571;NSC#716051:IND 61135) in Patients With Inoperable AJCC Stage III or IV Melanoma Harboring Somatic Alterations of C-KIT
The Oncopanel Pilot (TOP) Study
Who cites it
360 citing papers in PubMed, 5 syntheses or guidelines pooled it, 868 citations in OpenAlex.
- Defining and modeling 'cure' in early-stage melanoma: perspectives from a systematic literature review.Frontiers in oncology · 2026Pooled it
- A comprehensive review and case series of adjuvant and neoadjuvant therapies in acral melanoma with emerging insights from CT DNA testing.Frontiers in oncology · 2025Pooled it
- Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2.International journal of clinical oncology · 2024Guideline
- Systematic review and meta-analysis of genomic alterations in acral melanoma.Pigment cell & melanoma research · 2022Pooled it
- SEOM clinical guideline for the management of malignant melanoma (2017).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Guideline
- Phase II Study of Sunitinib in Tumors WithJCO precision oncology · 2024Trial
- Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.Cell reports. Medicine · 2024Trial
- Preclinical and Virtual Models of Mucosal Melanoma: Bridging Translational Gaps in a Rare and Lethal Cancer.Pigment cell & melanoma research · 2026Review
- Necrotic Liver Metastasis From Anorectal Mucosal Melanoma Mimicking a Pyogenic Liver Abscess: A Case Report.Cureus · 2026Article
- Role of KIT signaling in ovarian development and function: insights from multisystem biology†.Biology of reproduction · 2026Review
- Next-generation sequencing using a targeted gene panel in advanced solid tumors: five years of experience from an Italian referral institution.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Analysis of Treatment Patterns for Mucosal Melanoma Using Real-World Data in the SEER-Medicare-Linked Database.Cancer medicine · 2026Article
- Clinicopathologic characterization of primary anal canal mucosal melanomas: a single institution study.Virchows Archiv : an international journal of pathology · 2026Article
- Vertebral metastatic disease: A paradigm shift.Neuro-oncology advances · 2026Review
- Detection and surgical intervention in anorectal malignant melanoma: a case report.Journal of medical case reports · 2026Article
- Case Report: Penile malignant melanoma: insights from a three-case series and literature review on diagnosis and management.Frontiers in oncology · 2026Article
- Melanoma: Pathogenesis and Targeted Therapy.MedComm · 2026Review
- New Standards in the Treatment of Advanced Metastatic Melanoma: Immunotherapy and BRAF-Targeted Therapies as Emerging Paradigms.Current pharmaceutical design · 2026Review
- Research hotspots and trends of immunotherapy and melanoma: A bibliometric analysis during 2014-2024.Human vaccines & immunotherapeutics · 2025Article
- Review
300 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
18 authors at 1 institution in 1 country.
Funding
Abstract
contextSome melanomas arising from acral, mucosal, and chronically sun-damaged sites harbor activating mutations and amplification of the type III transmembrane receptor tyrosine kinase KIT. We explored the effects of KIT inhibition using imatinib mesylate in this molecular subset of disease.
objectiveTo assess clinical effects of imatinib mesylate in patients with melanoma harboring KIT alterations. DESIGN, SETTING, AND PATIENTS: A single-group, open-label, phase 2 trial at 1 community and 5 academic oncology centers in the United States of 295 patients with melanoma screened for the presence of KIT mutations and amplification between April 23, 2007, and April 16, 2010. A total of 51 cases with such alterations were identified and 28 of these patients were treated who had advanced unresectable melanoma arising from acral, mucosal, and chronically sun-damaged sites.
interventionImatinib mesylate, 400 mg orally twice daily.
main outcome measuresRadiographic response, with secondary end points including time to progression, overall survival, and correlation of molecular alterations and clinical response.
resultsTwo complete responses lasting 94 (ongoing) and 95 weeks, 2 durable partial responses lasting 53 and 89 (ongoing) weeks, and 2 transient partial responses lasting 12 and 18 weeks among the 25 evaluable patients were observed. The overall durable response rate was 16% (95% confidence interval [CI], 2%-30%), with a median time to progression of 12 weeks (interquartile range [IQR], 6-18 weeks; 95% CI, 11-18 weeks), and a median overall survival of 46.3 weeks (IQR, 28 weeks-not achieved; 95% CI, 28 weeks-not achieved). Response rate was better in cases with mutations affecting recurrent hotspots or with a mutant to wild-type allelic ratio of more than 1 (40% vs 0%, P = .05), indicating positive selection for the mutated allele.
conclusionsAmong patients with advanced melanoma harboring KIT alterations, treatment with imatinib mesylate results in significant clinical responses in a subset of patients. Responses may be limited to tumors harboring KIT alterations of proven functional relevance. Trial Registration clinicaltrials.gov Identifier: NCT00470470.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.